Search results for " Antibody variants"

Article Chromatography innovations for the diversified antibody pipeline
Introducing MabSelect™ VH3 affinity resin for antibody variants At Cytiva, we connect with process developers and manufacturers to understand their needs and strive to make t…

Article Chromatography innovations for the diverse antibody pipeline
For antibody variants, platform purification protocols for conventional mAb aren’t always providing sufficient outputs — some variants need new ligands, new base matrices, or new chromatography system…

Article Exploring the world of antibodies: mAbs, Fabs, dAbs, and bsAbs
Developing purification processes for antibody variants is not always straightforward and the platform approaches conveniently used for many traditional mAbs cannot be used. Learn more about develo…

Article Capture of Bispecific Antibodies and Removal of Product-Related Impurities
The biotherapeutics pipeline is becoming increasingly diverse as antibody variants such as bispecifics, conjugates, and fragments move through preclinical stages to commercial manufacturin…

Article Antibody purification quiz
Test your knowledge and gain insights in the purification of antibody variants – bsAbs, Fab, dAbs.

Article Chromatography processes for the diversified therapeutic antibody pipeline
The diversity of antibody variants in today’s pipeline presents unique challenges for purification and we see molecules such as bsAbs, Fabs, dAbs, and others. Conventional chromatography protocols, …

Article Preclinical Evaluation of Product Related Impurities and Variants
Preclinical Evaluation of Product Related Impurities and Variants The approaches for sample preparation of preclinical evaluation of safety and efficacy are addressed taking into consideration the s…

Article Quality by design for biotechnology products—part 1
A PhRMA Working Group's advice on applying QbD to biotech. By Taruna Arora, Roger Greene, Jennifer Mercer, Paul Tsang, Meg Casais, Stuart Feldman, Jutta Look, Tony Lubiniecki, Joseph Mezzatesta,…

Article Addressing the Challenges in Downstream Processing Today and Tomorrow
Newer classes of biotherapies will require innovations in processing technology. By Glen R. Bolton, Bernard N. Violand, Richard S. Wright, Shujun Sun, Khurram M. Sunasara, Kathleen Watson, Johna…

Article Get to know: mAb variants - eLearning
Key learnings are: - Structure and binding domains for antibody variants - Advantages and disadvantages of different antibody fragments - Design strategies for bispecific antibodies (bsAbs) …

Previous PageNext Page